A Unique Mammalian Suspension Technology Enhances Scalable rAAV Production with Pro10 Cell Line

Viralgen’s proprietary mammalian suspension technology, Pro10™, is a new innovation in the field of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. The Pro10™ cells are designed to improve efficiency and scalability in rAAV production, addressing the challenges of large-scale manufacturing in AAV gene therapies.

The Pro10™ cells have been fully characterized and licensed for gene therapy development by other biopharma companies, making them a trusted foundation for Viralgen’s robust and scalable rAAV vector manufacturing process. These cells have been optimized for rAAV production and scaled up to 2000L, demonstrating consistent and reproducible cell growth rates. They exhibit similar productivity in small and large-scale bioreactors and can produce different AAV serotypes.

The HEK293 derived animal component-free suspension Pro10™ cell line is described in detail in the PDF provided by Viralgen. This innovative technology offers a solution to the challenges faced in large-scale production of AAV vectors by reducing process development time and costs. The Pro10™ cells play a crucial role in Viralgen’s platform process for manufacturing AAV vectors and have been vital in producing groundbreaking gene therapies. Overall, the Pro10™ cells represent a promising advancement in the field of gene therapy manufacturing, offering a solution to the challenges faced in large-scale production of AAV vectors.

By Samantha Johnson

As a content writer at newsnmio.com, I craft engaging and informative articles that aim to captivate readers and provide them with valuable insights. With a background in journalism and a passion for storytelling, I thoroughly enjoy delving into diverse topics, conducting research, and producing compelling content that resonates with our audience. From breaking news pieces to in-depth features, I strive to deliver content that is both accurate and engaging, constantly seeking to bring fresh perspectives to our readers. Collaborating with a talented team of editors and journalists, I am committed to maintaining the high standards of journalism upheld by our publication.

Leave a Reply